GoodRx price target raised to $10 from $8 at Guggenheim

Guggenheim raised the firm’s price target on GoodRx to $10 from $8 and keeps a Buy rating on the shares after the company reported “strong results” in the quarter. While GoodRx lowered the high end of their 2023 revenue guidance range by about 2%, the firm believes that the company is going through a strategic shift through PBM partnerships and other initiatives that will fuel long-term growth, the analyst tells investors.